Qubiotech

Name

Qubiotech

Legal name

Qubiotech Health Intelligence S.L.

Website

https://qubiotech.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Medical Imaging AI Software / Neuroimaging Analytics

NAICS

Software Publishers (5132), Computer Systems Design and Related Services (54151)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

akta.pro secondary industry

Medical Imaging AI (HDAAAEAH)

Keywords

• AI medical imaging
• Neuroimaging analysis
• Biomarker quantification
• PET SPECT MRI software
• Clinical decision support

Headquarters

HQ city

A Coruña

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Neurocloud Platform Licensing: Qubiotech generates revenue through licensing its Neurocloud neuroimaging analysis platform to hospitals and healthcare institutions. As a CE-marked medical device manufacturer authorized by AEMPS (Spanish Agency of Medicines and Health Products), the company commercializes its software solutions to healthcare providers for use in routine clinical practice. The platform is offered as a SaaS solution requiring no installation, suggesting a subscription or per-use licensing model.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Qubiotech develops and licenses Neurocloud, a CE-marked cloud-based AI platform that automatically processes and quantifies neuroimaging biomarkers from PET, SPECT, and MRI brain scans. The platform integrates with hospital PACS systems, performs automatic data anonymization, compares results against healthy control databases, and generates customizable clinical reports within minutes for use by neurologists, nuclear medicine physicians, and radiologists. It is offered as four specialized modules (PET, SISCOM, VOL, SPECT) targeting neurodegenerative disease diagnosis and monitoring.

Product overview

Qubiotech offers Neurocloud, a cloud-based platform with modular add-on products for AI-assisted neuroimaging analysis. The core Neurocloud platform provides automatic quantification of brain imaging biomarkers from PET, SPECT, and MRI scans. Four specialized modules extend the platform: Neurocloud PET for amyloid and FDG PET quantification, Neurocloud SISCOM for epilepsy focus localization via SPECT subtraction, Neurocloud VOL for MRI volumetry and lesion analysis, and Neurocloud SPECT for Parkinson's diagnosis via DaT-SPECT. All solutions carry CE marking and are authorized by AEMPS (Spanish Agency of Medicines and Medical Devices). The platform is used in over 20 hospitals across Spain and Portugal, with more than 4,000 successful analyses completed.

Differentiator

Problem solved

Functional benefit

Brands

• Neurocloud: Automatic processing platform for neuroimaging to assist in detection and monitoring of brain diseases. Supports PET, SPECT, and MRI imaging modalities.

Products and services

• Neurocloud Platform

Named customers11 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core.

• EIT HealthcoreStrategic or Co-development PartnerQubiotech was one of 15 European startups participating in the EIT Health Product/Market Fit accelerator of the European Institute of Technology. This partnership enabled access to the British market and provided strategic guidance for market expansion.
• IDIS (Health Research Institute Foundation Santiago de Compostela)coreStrategic or Co-development PartnerQubiotech maintains a close relationship and R&D collaboration agreements with the Experimental Molecular Imaging Unit (UNIME-IDIS). The platform is located in the Nuclear Medicine Service of the Hospital Clínico de Santiago de Compostela. The IDIS Molecular Imaging Group, led by Prof. Dr. Álvaro Ruibal and Dr. Pablo Aguiar, supports the company's R&D activities.
• CIBER-BBNcoreStrategic or Co-development PartnerQubiotech collaborates with the GIB-UB research group led by Dr. Pavía in the PET-AC project, selected in the fourth call for Transfer Projects of the Center for Online Biomedical Research (CIBER-BBN). The objective is to improve the Neurocloud-PET product with new clinically validated functions for early detection of Alzheimer's disease.
• GiMO-PD Project ConsortiumcoreStrategic or Co-development PartnerQubiotech participates in the GiMO-PD project (RTC2019-7150-1) funded by the Ministry of Science and Innovation. The consortium of 3 companies and two public research organizations aims to develop a solution for personalized management of patients with Parkinson's disease. Qubiotech develops SPECT image analysis software that identifies characteristic disease biomarkers.
• Gallaecia POCTEP ProjectcoreStrategic or Co-development PartnerQubiotech participates as a partner in the Gallaecia POCTEP Project, a cross-border initiative uniting Portuguese and Galician entities to enhance PET medical imaging capabilities. The project integrates research centers, hospitals, universities, and companies to advance PET technology, with Qubiotech contributing expertise in AI-assisted medical image analysis.
• ACIS/SERGAScoreStrategic or Co-development PartnerQubiotech was selected by ACIS (Axencia de Coñecemento en Saúde) within the Living Lab Ourense to integrate its neuroimaging analysis project at the Complejo Hospitalario Universitario de Ourense. The project aims to incorporate advanced neuroimaging quantification techniques into routine clinical practice in the public health system.
• Hospital Clinic de BarcelonacoreStrategic or Co-development PartnerQubiotech and Hospital Clinic de Barcelona have reinforced their collaboration in the use of AI for neuroimaging through a new agreement. Dr. Xavier Setoain from the hospital co-authored the epileptogenic focus location method implemented by Neurocloud-SISCOM.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• icometrix: icometrix provides AI-based quantitative analysis of brain MRI and CT scans (e.g., MS, dementia, traumatic brain injury) with regulatory clearances in the U.S. and EU. It is a direct competitor to Qubiotech's Neurocloud, addressing the same hospital neurology/radiology buyers with similar AI-quantification workflows.
• Cortechs.ai: Cortechs.ai (previously CorTechs Labs) offers NeuroQuant, a leading FDA-cleared MRI brain volumetry tool used in clinical practice. It directly overlaps with Qubiotech's Neurocloud VOL and is sold into the same radiology/neurology hospital customers.
• QMENTA: QMENTA provides a cloud-based neuroimaging analysis platform for clinical trials and clinical practice, offering multi-modal MRI/PET quantification. It competes with Neurocloud for neuroimaging biomarker quantification workflows in research and hospital settings.

Emerging players

• Subtle Medical: Subtle Medical applies AI to accelerate and improve MRI and PET image acquisition and post-processing. It addresses a closely adjacent AI-for-neuroimaging space and shares hospital radiology/nuclear medicine buyers with Qubiotech.
• Aidoc: Aidoc is an AI imaging platform for radiology triage and quantification across multiple modalities, with FDA-cleared products. While broader in scope (CT, X-ray, MRI), it competes for the same hospital AI-imaging budget and could expand into Qubiotech's neuroimaging territory.
• Blackford Analysis: Blackford Analysis provides an AI application marketplace and orchestration layer for medical imaging, including neuroimaging tools. It is an adjacent platform competitor to Neurocloud's hospital imaging AI workflow.
• Arterys: Arterys offers cloud-native AI medical imaging platforms (MICA) with FDA-cleared neuroimaging and cardiac quantification modules. It directly competes with Neurocloud in cloud-based AI quantification of brain MRI/CT for hospital use.

Broad incumbents

• Siemens Healthineers (syngo.via): Siemens Healthineers' syngo.via is a leading enterprise imaging post-processing platform used in hospitals worldwide, including neurology and oncology quantification. As a broad incumbent with deep hospital integration, it represents the larger vendor competition Qubiotech faces.
• GE HealthCare (Edison): GE HealthCare's Edison platform and Centricity imaging suite offer AI-driven post-processing, including brain and PET analytics. It competes for hospital imaging AI spend via bundled modality-and-software enterprise deals.
• Philips (IntelliSpace AI): Philips' IntelliSpace AI and radiology post-processing portfolio include neuroimaging quantification and clinical decision support, often sold as part of broader enterprise imaging contracts. It is a broad incumbent competing for the same hospital budget as Qubiotech.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/qubio
• LinkedInlinkedin.com/company/qubiotech-health-intelligence
• Facebookfacebook.com/qubiotech

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qubiotech